If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Statement

17 Aug 2006 07:44

Stanelco PLC17 August 2006 Stanelco PLC17 August 2006 Stanelco PLC ("Stanelco" or "the Company") 17 August 2006 Trading update The Company announced on the 14th July 2006 in its interim results for the sixmonth period ending 30 April 2006 that its closing cash position at 30 April2006 was GBP0.3m. The Company started the period with a cash balance of GBP4.4mand made investments in research and development of GBP0.6m and increased itslevels of stock from GBP2.6m at the year end to GBP3.1m. The Company alsoinvested GBP1.2m in capital expenditure in the period. Since the half year end, the Company raised GBP3.7m (net of expenses) by way ofan equity placing in June 2006 of which GBP1.6m was used to meet a stage paymentfor the acquisition of Biotec and GBP2.1m was for working capital purposes. Ofthat GBP2.1m, GBP2.0m has been used for the ongoing commercialisation of theGroup's technologies and meeting the Group's operational running expenses since1 May 2006, and GBP0.1m has been used for capital expenditure. The Company also stated in those interim results that it was considering itsfunding requirements and funding options for the next phase of its development.As at today's date the Company has cash at bank of GBP0.9m with an unusedoverdraft facility of GBP0.2m. The Company estimates that its current cash at bank of GBP0.9m, together withprojected receivables and working capital needs is sufficient to meet its cashrequirements for a further three months in the absence of further funding or newrevenue streams commencing in the period. Since 2000, Stanelco's business model has transformed from a manufacturer andsupplier of capital goods into an intellectual property company with interestsin markets with significant growth potential, which include sustainablepackaging and environmentally responsible sealing solutions for the packagingindustry. As indicated in the interim results, in order to enable the Group to move intothe next phase of the commercialisation of its intellectual property portfolioand to meet its working capital requirements, the Company is currently exploringall financing options including a public equity issue. The Company will update the market once any further information is available. Martin Wagner, Stanelco Chief Executive said: "While the Company is exploring all of its financing options, it continues toactively progress the commercialisation of its products. The Company is in advanced negotiations with a number of potential joint venturepartners in the USA to compound biodegradable resin. This is to meet thedemands currently expressed to Stanelco by major multiple retailers and globalfast food chains. Letters of intent with two of these companies have beenexchanged and the Company believes that these will lead to contracts in theshort term. We acknowledge that Stanelco has encountered delays in rolling out GREENSEAL tothe market. The delays have primarily resulted from the limitations of the foodpackaging industry to allow access to machines to test the technology in afactory environment. The Board believes that these delays will not impact onthe potential success of the project." Contact Martin WagnerChief Executive02380 867 100 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.